Research Interests

Professor Yarnold is chief investigator of seven open national randomised clinical trials, including:

• Standardisation of Radiotherapy (START) Trials A & B
• Intensity Modulated Radiotherapy (IMPORT) Trials evaluating partial breast radiotherapy (IMPORT Low) and dose intensity modulated radiotherapy (IMPORT High)
• Hyperbaric Oxygen Trial (HOT II) in patients with adverse effects of pelvic radiotherapy
• FAST trial of hypofractionated radiotherapy
• FAST-Forward trial testing a 5-fraction schedule of whole breast radiotherapy delivered in one week

These trials are linked to translational research investigating cell and genetic predictors of normal tissue injury. Associated correlative research in collaboration with colleagues at the University of Oxford investigates the molecular basis of fractionation sensitivity.